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Abstract
Background: Many Gram-positive pathogens aggregate and activate platelets in vitro and this has been proposed to
contribute to virulence. Platelets can also form complexes with neutrophils but little is however known about platelet and
platelet-neutrophil responses in bacterial infection.
Methodology/Principal Findings: We added isolates of Gram-positive bacteria from 38 patients with a bacteremic infection
to blood drawn from the same patient. Aggregometry and flow cytometry were used to assess platelet aggregation and to
quantify activation of platelets, neutrophils, and platelet-neutrophils complexes (PNCs) induced by the bacteria. Fifteen
healthy persons served as controls. Most isolates of Staphylococcus aureus, beta hemolytic streptococci, and Enterococcus
faecalis induced aggregation of platelets from their respective hosts, whereas pneumococci failed to do so. S. aureus isolates
induced platelet aggregation more rapidly in patients than in controls, whereas platelet activation by S. aureus was lower in
patients than in controls. PNCs were more abundant in baseline samples from patients than in healthy controls and most
bacterial isolates induced additional PNC formation and neutrophil activation.
Conclusion/Significance: We have demonstrated for the first time that bacteria isolated from patients with Gram-positive
bacteremia can induce platelet activation and aggregation, PNC formation, and neutrophil activation in the same infected
host. This underlines the significance of these interactions during infection, which could be a target for future therapies in
sepsis.
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Introduction
Sepsis remains a major cause of mortality, causing over 200 000
deaths annually in the US alone [1]. Although substantial
advances have been made in the understanding of this disease
[2], these new insights have not yet translated into successful
therapeutic strategies [3].
Sepsis is the consequence of a complex host response to an
invading microorganism [4]. Invading bacteria are recognized by
innate immune cells leading to the release of multiple cytokines
which in concert with the activation of other defense systems can
result in the clinical picture known as systemic inflammatory
response syndrome (SIRS).
While most of the attention in the sepsis field has been devoted
to traditional immune cells, there is mounting evidence that
platelets are essential not only in coagulation but that they are also
important in inflammation and defense against infection [5]. Most
of the Gram-positive pathogens that commonly cause sepsis,
including Staphylococcus aureus, beta hemolytic group A streptococci
(GAS), as well as several other streptococcal species and
Enterococcus faecalis are known to activate and aggregate human
platelets [6,7,8,9]. The molecular mechanisms leading to platelet
activation has been described in detail for many bacterial species,
and it is clear that host factors such as specific Immunoglobulin G
(IgG) play an important role [10,11,12,13,14,15]. In support of a
role for platelets in defense against Gram-positive bacterial
infection, thrombocytopenia in patients with S. aureus bacteremia
is associated with poor prognosis [16].
Platelets and polymorphonuclear granulocytes are known to
adhere to each other and form platelet-neutrophil complexes
(PNCs). Platelet P-selectin and the Mac-1 complex of neutrophils
have been shown to be the main regulators in the formation of
PNCs [17,18,19], PNCs have been proposed to play a role in the
development of multi-organ failure in severe disease due to
increased sequestration in liver sinusoids and pulmonary capillar-
ies [20], as well as in promoting neutrophil activation and
migration, and in the formation of neutrophil extracellular traps
which can ensnare bacteria [21].
Despite evidence that there are important links between
platelets, bacteria and leukocytes, the specific role of these
interactions during infection has yet to be elucidated. Relatively
few studies have been carried out on host platelet and neutrophil
responses to specific pathogens: Peters et al. [22] investigated
platelet-neutrophil interactions in severe meningococcemia and
found that it was associated with neutrophil but not platelet
activation and suggested that the PNC formation seen in this
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compared platelet and leukocyte response to oral bacteria in
patients with periodontitis to that in healthy controls and found
that all bacteria tested induced PNC formation.
Collectively, the data from in vitro studies imply that platelet-
bacteria interactions may be important during infection. In this
study we have enrolled 38 patients with Gram-positive bacteremia
and we studied platelet-neutrophil interactions in patient blood in
response to the invading bacterium.
Results
Patients and isolates
Patients were included from February of 2009 through May of
2010. All 38 patients included in the study were judged to have an
infection by the responsible physician. Patient characteristics are
shown in Table 1, where they are grouped according to isolate.
Sixteen patients were female and 22 were male. The mean age was
67 years (range, 23–98). Seven patients had diabetes mellitus, 6
had chronic obstructive lung disease, and 4 had congestive heart
failure. Nine patients did not have any apparent underlying
disorder. The most common bacterium isolated was S. aureus
(n=13), followed by S. pneumoniae (n=11), GAS (n=4) and beta-
hemolytic group G streptococci (GGS) (n=2), enterococci (n=5),
alpha-hemolytic streptococci (n=3), and group B streptococci
(GBS) (n=1). Given the many similarities between the beta-
hemolytic streptococci (BHS) [24], these bacteria were considered
as one entity in all statistical analyses.
The most common focal infection was pneumonia (n=9)
followed by infectious endocarditis (IE) (n=8, of which one case
was pacemaker endocarditis). Seven patients had a skin or soft
tissue infection, and 4 patients had septic arthritis. In 6 cases no
focal infection was found.
At admittance 24 of the 38 patients fulfilled the SIRS-criteria
[25], displaying two or more of temperature ,36uCo r.38uC;
heart rate .90 beats per minute; respiratory rate .20 per minute;
leukocyte count of .12610
9 L
21 or ,4610
9 L
21. No patient had
organ dysfunction at the time of experiment as judged by the result
of standard blood analyses. On the day of experiment, 10 patients
still met the SIRS-criteria. At the time of experiment, median
platelet count was 235610
9 L
21 or (interquartile range,
160610
9 L
21–319610
9 L
21) and median neutrophil count was
7.1610
9 L
21 (5.1610
9 L
21–9.4610
9 L
21).
Nine patients were investigated within 48 hours after blood
cultures had been taken, 9 were investigated between 48 and
72 hours, and another 9 were investigated within 72 to 96 hours
after cultures had been drawn. Eleven patients were investigated
between 96 and 120 hours after blood cultures had been obtained.
Thirteen patients, including all patients infected with entero-
cocci, were taking, or had taken, aspirin, ibuprofen, or clopidogrel
in the previous ten days.
Of the 15 controls, 9 were male and 6 were female. The mean
age was 31 years (range, 23–54).
Platelet aggregation by clinical isolates of Gram-positive
bacteria
Pilot experiments using PRP from healthy donors and reference
isolates of S. aureus, S. pneumoniae, GAS, and E. faecalis,
demonstrated that all strains, with the exception of S. pneumoniae,
caused platelet aggregation within 25 minutes (data not shown).
The S. pneumoniae strain was also tested at a higher
concentration (final concentration of 1.6?10
8 bacteria/ml) but still
failed to induce platelet aggregation. All isolates from the patients
included in our study were tested for their ability to induce
aggregation of platelets in PRP from the respective patient.
Collagen was used as a positive control, and one patient (no. 14,
Table 1), whose platelets did not aggregate in response to collagen,
was excluded from further analysis of platelet aggregation. Eleven
of 13 isolates of S. aureus and 5 of 7 BHS isolates induced
aggregation, as did 2 of 5 enterococcal isolates. All isolates of S.
pneumoniae (n=10) and alpha hemolytic streptococci (n=3) failed
to induce aggregation. Time to aggregation was between 1 and
10 minutes (Fig. 1). For one aggregating S. aureus isolate it was not
possible to determine the lag time to aggregation.
Platelets from 5 of the 13 patients treated with an antiplatelet
drug responded with aggregation when stimulated with the
bacteria that had been isolated from their blood. The correspond-
ing number for platelets from patients not on antiplatelet
medication was 13 out of 24. There was no significant difference
using Fisher’s exact test in the distribution of platelet aggregating
isolates and antiplatelet treatment.
Platelet activation
Stimulation of platelets by ADP or by certain bacteria induces
activation marked by phenotypic changes and release of granules.
This was monitored by analyzing platelet-rich plasma by three-
color flow cytometry. Platelets were identified using a CD42
specific antibody and release of alpha granules was determined
using a CD62P specific antibody. The activation status of the
fibrinogen receptor (GPIIb/IIIa) was determined using PAC-1,
which is an antibody specific for the active conformation of the
receptor. PRP was incubated with either HEPES buffer, ADP, or
the bacterium isolated from the patient. The incubation time and
bacterial concentration was chosen as in an earlier study [8], and
pilot experiments showed that all reference strains, except S.
pneumoniae, induced platelet activation under these conditions (data
not shown). Platelet activation was determined for platelets in PRP
from healthy controls and from patients. The percentage of
platelets exhibiting the activation marker CD62P correlated with
the mean fluorescence intensity (MFI) of the same marker
(r=0.79, 0.86, and 0.88 with the Spearman correlation coefficient
for platelets incubated with buffer only, with ADP, or with
bacteria; data not shown).
The median percentage of activated platelets, as determined by
CD62P-presentation, in PRP of patients was 6.3 (interquartile
range, 4.9–12) as compared to 5.7 (5.2–7.0) in healthy controls.
Using the Mann-Whitney U test the difference was not significant
(P=0.47). The corresponding numbers after stimulation with ADP
were in patients 65 (56–75) and in healthy controls 68 (48–83)
percent (P=0.42 for a difference) (Fig. 2A). As judged by the
Kruskal-Wallis test there were no statistically significant differences
between platelet activation by buffer only or by ADP in patients
infected by the different organisms studied (Fig. 2A). Patients
no. 14, 18, 20, 30, 31, 32, and 35 were excluded from the analyses
of platelet activation since platelets in PRP from these patients
were either too few to be measured, had aggregated before flow
cytometry or failed to respond to ADP.
Platelet activation in patient PRP by bacteria isolated from the
respective patient varied depending on the organism. In Figure 2B,
bacterial activation of platelets (as determined by CD62P-
presentation) is shown relative to the activation induced by
ADP. BHS activated platelets to a significantly higher extent than
S. aureus (P=0.0015 with the Mann-Whitney U test), but not
significantly more than S. pneumoniae (P=0.13). S. aureus did not
activate platelets significantly more than did buffer alone (P=0.07
with the Wilcoxon matched-pairs signed rank test), while S.
pneumoniae induced significantly more activated platelets than
buffer did (P=0.04).
Platelet and Neutrophil Responses to Bacteremia
PLoS ONE | www.plosone.org 2 November 2011 | Volume 6 | Issue 11 | e26928The increase in platelet activation by bacteria relative to
activation by ADP was not higher among the aggregating than
the non-aggregating isolates (P=0.42 using the Mann-Whitney U
test) (Fig. 2C). Many S. aureus isolates failed to induce platelet
activation as judged by the FACS-analysis even though they
induced aggregation as judged by turbidometry. Thus, if the
isolates of S. aureus (depicted with crosses in Fig. 2C) were
excluded, the remaining aggregating isolates induced significantly
Table 1. Patient characteristics.
Patient
Gender
(Age) Bacterium Focal infection Underlying disorders
Antiplatelet
medication
SIRS signs on day
of admittance
SIRS signs on day
of experiment
1 F (76) S. aureus Cutaneous carbuncle DM (type II) - 2/4 0/4
2 M (77) S. aureus Pneumonia COPD, CHF A, C 2/4 2/4
3 M (72) S. aureus Septic arthritis COPD, vasculitis - 2/4 2/4
4 M (73) S. aureus Cellulitis Colon cancer - 0/3 0/4
5 M (39) S. aureus Unknown Nephrostomy, Colostomy - 1/3 1/4
6 M (23) S. aureus IE Dermatitis - 2/4 0/3
7 F (65) S. aureus Pneumonia DM (type II) A 1/1 1/4
8 M (91) S. aureus In diabetic leg ulcers DM (type II) A 2/4 1/4
9 F (42) S. aureus Pacemaker endocarditis Pacemaker - 1/3 0/4
10 M (77) S. aureus Unknown CHF A, C 1/3 0/4
11 F (98) S. aureus IE Nasal cavity cancer, CHF - 3/3 1/4
12 M (59) S. aureus Unknown CMT - 2/3 1/4
13 F (84) S. aureus IE Pacemaker, CHF, PBC - 2/3 0/4
14 M (71) S. pneumoniae Septic arthritis DM (type I) A 2/4 0/1
15 M (49) S. pneumoniae Pneumonia None - 4/4 3/4
16 F (65) S. pneumoniae Pneumonia COPD I 0/1 1/4
17 M (87) S. pneumoniae Pneumonia None A 1/4 0/4
18 F (58) S. pneumoniae Pneumonia COPD, Asthma - 2/4 1/3
19 F (74) S. pneumoniae Pneumonia COPD - 2/4 0/4
20 F (42) S. pneumoniae Pneumonia None - 1/4 4/4
21 M (39) S. pneumoniae Acute sinusitis None - 1/4 0/4
22 F (57) S. pneumoniae Unknown None - 2/4 3/4
23 F (67) S. pneumoniae Pneumonia DM (type II) A 2/3 2/4
24 F (64) GAS Septic arthritis None - 2/3 2/4
25 M (84) GGS In necrotic foot ulcers Necrotic foot ulcers - 1/4 1/4
26 M (88) GGS In chronic leg ulcers Chronic leg ulcers - 2/4 2/4
27 F (40) GAS Para-pharyngeal abscesses None - 2/3 2/4
28 M (75) GAS Wound infection DM (type II), Urinary
bladder cancer
- 2/4 0/4
29 M (75) GAS Septic arthritis None - 3/4 2/3
30 M (80) E. faecalis Unknown DM (type II) A 2/2 0/4
31 M (74) E. faecalis IE Prosthetic heart valve A 2/4 0/4
32 M (84) E. faecalis Unknown Long-term indwelling
catheter, COPD
A 1/4 1/4
33 M (73) E. faecalis Pyelitis Prostatic hypertrophy A 4/4 1/4
34 F (71) E. faecium Post-surgical abdominal
infection
Gastro-intestinal
carcinoid
A, I 2/2 0/4
35 M (67) S. mutans IE, Infectious spondylitis None - 0/4 0/4
36 F (74) S. gordonii IE Prosthetic heart valve - 2/4 0/4
37 M (48) S. mitis IE Mitral insufficiency - 0/4 1/4
38 F (74) GBS Erysipelas Lymphedema - 2/4 0/4
Abbreviations: M=Male. F=Female. SIRS=systemic inflammation response syndrome. Numbers are given as the parameters fulfilled by the number parameters
registered. For definitions, see the text.
IE=Infectious endocarditis. DM=Diabetes mellitus. COPD=Chronic Obstructive Pulmonary Disease. CHF=Congestive heart failure. CMT=Charcot-Marie-Tooth Disease.
PBC=Primary biliary cirrhosis.
GAS=Group A streptococcus. GGS=Group G streptococcus. GBS=Group B streptococcus. A=Aspirin. C=Clopidogrel. I=Ibuprofen.
doi:10.1371/journal.pone.0026928.t001
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(P=0.035).
Activation of platelets from patients and controls as determined
by the percentage of platelets expressing the active conformation
state of GPIIb/IIIA did not differ significantly compared to the
activation determined by the percentage of platelets positive for
CD62P (see Data S1). In Data S1, numerical values for platelet
activation, neutrophil activation, and PNC formation are given for
each patient.
Neutrophil activation
Upon activation, neutrophils increase the expression of CD11b,
which together with CD18 form the Mac-1 complex that is
important for adhesion and migration [26]. We monitored the
level of neutrophil activation by determining the surface
expression of CD11b, measured as the MFI.
Median MFI of CD11b on neutrophils in blood from patients
was 67 (interquartile range, 50–100), which was statistically
significantly higher than the level in healthy controls that was 32
(23–37) (P,0.0001) (Fig. 3A). Stimulation of neutrophils in blood
from patients with ADP and formyl-methionyl-leucyl-phenylala-
nine (fMLP) in combination (ADP/fMLP) increased the MFI of
CD11b to a median of 223 (153–325) and to 143 (55–196) in
healthy controls (P=0.008 for a difference with the Mann-
Whitney U test). As judged by the Kruskal-Wallis test there were
no statistically significant differences between MFI of CD11b on
neutrophils from patients infected by different bacteria, either in
buffer or after stimulation with ADP/fMLP (Fig. 3A). Isolates from
patients no. 14, 24, 30, 31, and 35 were not included in the
analyses of neutrophil activation since expression of CD11b was
not determined for these patients.
Stimulation of neutrophils from patients with their respective
bacterium resulted in a varied response. This is shown in Fig. 3B
as the increase in activation induced by the bacteria relative to that
induced by ADP and fMLP. Most bacterial isolates induced
surface expression of CD11b on neutrophils to approximately the
same extent as ADP/fMLP did. S. pneumoniae and S. aureus induced
significantly more neutrophil activation than BHS (P=0.007 and
P=0.045). Other differences were not significant. Two patients,
one infected with S. aureus and one with GAS, were excluded from
the latter analyses since ADP/fMLP failed to cause an increase in
MFI of CD11b.
Platelet-neutrophil complexes
The formation of complexes of neutrophils and platelets was
determined as the percentage of neutrophils positive for the
platelet marker CD61 which is present at the surface of resting and
activated platelets.
The median percentage of PNCs in whole blood from patients
was 8.9 (interquartile range, 6.9–18.3) as compared to 7.0 (5.9–9.4)
in healthy controls (P=0.04 for a difference with the Mann-
Whitney U test). After stimulation with ADP/fMLP the median
percentage of neutrophils in complex with platelets were 51 (37–
79) in patients and 27 (21–31) (P=0.0005) in controls. As judged
by the Kruskal-Wallis test there were no statistically significant
differences between the percentages of PNCs in patients infected
by different organisms (Fig. 4A). Patients no. 14, 30, 31, and 35
were not included in the analyses of PNC formation.
Stimulation of blood from patients with their respective
bacterium resulted in most cases in increased PNC formation.
As judged by the Kruskal-Wallis test there was no significant
difference in the relative increase in PNCs induced by different
bacteria (Fig. 4B). However, using the Wilcoxon’s matched-pairs
signed rank test, S. pneumoniae isolates induced significantly less
PNC formation than ADP/fMLP in the respective patients
(P=0.002).
Platelet and neutrophil responses to S. aureus in patients
and healthy controls
The apparent discrepancy in the ability of the isolates of S. aureus
in our study to cause platelet aggregation and platelet activation in
PRP of patients made us investigate how these isolates affect
platelets and neutrophils from 5 healthy donors. The results are
summarized in Figs. 5A–D. Most isolates (10/13) aggregated
platelets from 4 or all 5 donors, and 2 isolates aggregated platelet
from 3 donors. Notably, the S. aureus isolated from patient no. 7
failed to induce aggregation in the patient as well as in all 5 healthy
donors. There was a tendency for shorter time to aggregation in
the patients as compared to the donors. The difference reached
significance for donor 1 (P=0.0051), donor 3 (P=0.005), and
donor 5 (P=0.02), and were close to significance for donor 2
(P=0.09) and donor 4 (P=0.07) using the Mann-Whitney U test
(Fig. 5A). One aggregating isolate was excluded from this analysis
since it was not possible to determine the lag time to aggregation
for this isolate in PRP from the patient.
Platelet activation by the S. aureus isolates expressed as the
increase in the percentage of CD62P positive platelets relative to
the increase induced by ADP is shown in Figure 5B. The relative
increase in platelet activation, as determined by the percentage of
CD62P positive platelets, by the S. aureus isolates was significantly
higher in 3 of the 5 donors as compared to the relative increase by
the respective isolate in its patient (P-values=0.01, 0.0002, and
0.0015 for donors 2, 4, and 5, respectively with the Mann-Whitney
U test). In donor 3, no isolate induced significant activation. For
platelet activation, as determined by the percentage of platelets
expressing the active conformation of GPIIb/IIIa-receptor, the
relative increase in platelet activation by the S. aureus isolates was
significantly higher in donors 1, 2, and 4 (P-values=0.03, 0.007,
and 0.0002) than in patients (data not shown).
Figure 1. Platelet aggregation by Gram-positive pathogens.
Time to aggregation of platelets in PRP from patients is shown. Filled
circles depict aggregating isolates. Below the diagram are the numbers
of aggregating isolates divided by the total number of isolates of the
respective species presented. Abbreviations, which are used through-
out the figures, are Staphylococcus aureus (S. a), Streptococcus
pneumoniae (S. pne), beta-hemolytic streptococci (BHS), enterococci
(Ent), and alpha-hemolytic streptococci (a-strep).
doi:10.1371/journal.pone.0026928.g001
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with a median activation of 1.2 (interquartile range 0.62–1.7)
relative to the activation of induced by ADP/fMLP (Fig. 5C).
There was a tendency toward greater neutrophil activation by S.
aureus in the patients than in the healthy controls; however, the
increase induced by the bacteria relative to that induced by ADP/
fMLP was significantly higher in patients only compared to one
donor (donor 4) (Fig. 5C).
PNC formation in response to S. aureus relative to that induced
by ADP/fMLP was significantly higher in patients than in donor 1
and 2 (P=0.02 and P=0.02 using the Mann-Whitney U test)
(Fig. 5D).
Discussion
Despite numerous studies on bacterial platelet aggregation
induced by bacteria this is the first report where bacteria have
been tested in blood from the host they had infected. This is very
relevant since platelet aggregation is in most cases IgG-dependent
and thus donor dependent [6,8,27]. Earlier studies have relied on
healthy platelet donors, and even among such subjects platelet
aggregation in response to bacteria can be variable [8,28]. The
current study uses an in vivo-like setup to demonstrate that most
isolates of S. aureus, GAS, GGS, and E. faecalis, can induce platelet
aggregation in their host. This provides evidence that platelet
aggregation by bacteria can occur during severe infections and
may be an important event. We have also demonstrated that PNC
formation and neutrophil activation was more abundant in
baseline samples from patients than in healthy controls and that
most bacterial isolates induced additional PNC formation and
neutrophil activation.
Most of the S. aureus isolates in our study induced aggregation of
platelets from their respective hosts as well as from healthy
controls. Using PRP from healthy donors, a lower frequency of
Figure 2. Platelet activation in healthy controls and in patients. (A) Platelet activation in healthy controls (ctrls), in all patients (pts), and in
patients grouped by their respective infective organism. Platelet activation is shown as the percentage of CD 62-positive platelets in response to
buffer only (open bars) or to ADP (grey bars). In (B) the increase in activated platelets in response to different bacterial isolates compared to buffer
relative to the increase caused by stimulation by ADP compared to buffer is shown. Values are expressed as medians 6 interquartile range. *P,0.05
after Mann-Whitney U testing. In (C) the percentage of CD 62-positive platelets in response to bacteria in patient blood is shown in two groups. To
the left, patients responding with platelet aggregation to the bacterium are shown and to the right patients not responding with aggregation to the
bacterium are depicted. Crosses represent S. aureus, while filled circles represent other bacteria. The difference between the groups is significant only
if the results obtained with the S. aureus isolates are excluded.
doi:10.1371/journal.pone.0026928.g002
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isolates of S. aureus [11]. Whereas we observed no differences in the
frequency of aggregation induced by S. aureus isolates between
patients and controls, aggregation occurred more rapidly in
patients though the differences did not always reach statistical
significance. The faster aggregation could be attributable to higher
antibody levels, increased platelet reactivity due to the inflamma-
tory process in the patients, or perhaps higher levels of the acute
phase protein fibrinogen which is important for several types of
bacterial platelet aggregation [10,13,14,15]. In the light of these
findings we were surprised that the same S. aureus isolates failed to
induce platelet activation in the patients. We therefore studied the
platelet activation in response to these isolates also in healthy
donors and found that platelet activation occurred in most donors.
Since platelet aggregation occurred in response to the S. aureus
isolates, we find it likely that this was preceded by platelet
activation also in the patients but that our method and detection at
a single fixed time-point and bacterial-platelet ratio failed to
demonstrate this. Our method could however detect both
streptococcal and enterococcal platelet activation in the patients
and, as mentioned above, the S. aureus isolates induced activation
in most healthy controls. Hence, we cannot formally exclude the
possibility that platelet aggregation and activation may not reflect
identical molecular processes in patients with bacteremia. This
merits further investigations.
The lack of platelet aggregation by S. pneumoniae in the PRP of
patients was also somewhat surprising since an earlier study had
indicated that this bacterium can aggregate platelets [9]. In
addition, a very recent paper also demonstrated strain dependent
platelet aggregation by S. pneumoniae [29]. Both these reports used
higher concentrations of bacteria than was used in this study. Since
platelet aggregation is known to be dependent on the ratio
between bacteria and platelets [8,30,31] the differences in
bacterial concentration could perhaps explain why we did not
observe platelet aggregation by S. pneumoniae.
Interestingly, we found no significant differences in platelet
aggregation by bacteria between patients treated with an
antiplatelet drug or patients without such treatment. The power
of the study to detect such differences was very limited, since
relatively few patients were taking antiplatelet medication and
since those patients were infected with different organisms. Despite
this, our findings suggest that bacteria may activate and aggregate
Figure 3. Neutrophil activation in healthy controls and in patients. (A) Neutrophil activation in healthy controls, in all of the patients, and in
patients grouped by their respective infective organism. Neutrophil activation is given as the MFI of CD11b in response to buffer only (open bars) or
ADP/fMLP (grey bars). Values are 6 interquartile range. In (B) the increase in MFI of CD11b by different bacteria relative to the increase caused by
stimulation of ADP is shown. *P,0.05, **P,0.01, ***P,0.001 after Mann-Whitney U testing.
doi:10.1371/journal.pone.0026928.g003
Figure 4. Formation of platelet-neutrophil complexes in healthy controls and in patients. (A) The percentage of PNCs is expressed as the
percentage of neutrophils positive for the platelet marker CD61 in response to buffer only (open bars) or ADP/fMLP (grey bars). Values are 6
interquartile range. In (B) the increase in PNCs induced by different bacterial isolates relative to the increase caused by ADP/fMLP is shown. *P,0.05
and ***P,0.001 with Mann-Whitney U test.
doi:10.1371/journal.pone.0026928.g004
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addition, the platelets of patients treated with aspirin responded
both to collagen with aggregation and to ADP with activation
(data no shown) to the same extent as platelets from the patients
not treated with aspirin. Elderly patients and patients with multiple
diseases which increase the risk for sepsis are more likely to receive
anti-platelet drugs. Thus, the impact of such medication on the
role of platelets and PNCs in sepsis should to be taken into
consideration in future studies.
We also demonstrate that most bacterial isolates induce PNCs
in the blood of their hosts indicating that such complexes are
formed during infection. Our finding that PNCs are more
prevalent in the blood of patients with Gram-positive bacteremia
than in healthy controls is in agreement with previous studies that
describe a higher presence of PNCs in uncomplicated septic
episodes but decreased PNC-levels in sepsis complicated by organ
failure, focusing on the first 24 hours of disease [20,32,33,34].
None of our patients had organ failure at the time of the
experiments. Most previous studies have reported elevated platelet
activation in sepsis, but we did not observe this in our patients.
These diverging results might reflect changes in the inflammatory
state occurring during the lag time from the onset of disease to the
time our experiments were carried out. We did observe that
neutrophils from patients were significantly more activated than
neutrophils from healthy controls. This is in agreement with Peters
et al. who found that there is increased neutrophil but not platelet
activation at an early stage in severe meningococcemia [22]. To
promote understanding of platelet-leukocyte interactions in severe
infectious disease, platelet activation and platelet-neutrophil
interactions should be monitored during different stages of and
time points during sepsis.
Our findings indicate that bacterial induced platelet aggregation
and PNC-formation are likely to occur in infections with Gram-
positive bacteria. This underlines the importance of interactions
between bacteria, platelets, and leukocytes in invasive bacterial
disease. A better understanding of how these cells interact, and the
consequences of such interactions, may be valuable for develop-
ment of novel strategies for the treatment of sepsis.
Figure 5. Platelet and neutrophil responses to clinical blood isolates of S. aureus. (A) Time to platelet aggregation in PRP by 13 S. aureus
isolates is shown. In the left part of the figure, time to aggregation in PRP of patients with S. aureus bacteremia is shown. Time to aggregation in the
five healthy donors (labeled 1–5) is shown in the right part of the figure. In the bottom of the figure, the number of isolates inducing aggregation of
platelets is given. (B) The increase in activated platelets by the 13 S. aureus isolates relative to the increase caused by stimulation of ADP is given for
the patients and for the five donors (1–5). (C) The increase of MFI of CD11b on neutrophils induced by the 13 S. aureus isolates relative to the increase
caused by stimulation of ADP/fMLP is given for the patients and for the five donors. (D) The increase in PNCs induced by the 13 S. aureus isolates
relative to the increase caused by stimulation of ADP/fMLP is given for the patients and for the five donors. One value in (D) is above five (8.3) and is
depicted on the outer line of the graph. A filled circle represents each isolate. Medians are given as lines. *P,0.05, **P,0.01, ***P,0.001 after Mann-
Whitney U testing.
doi:10.1371/journal.pone.0026928.g005
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Ethics statement
The regional Ethical Review Board in Lund approved the study
(reference number 657/2008), and written informed consent was
obtained.
Patients and controls
Patients aged 18 or above treated at the Clinic for Infectious
Diseases, and patients treated in cooperation with an infectious
disease specialist at other clinics at Ska ˚ne University Hospital,
Lund, Sweden, with one or more blood cultures positive for a
Gram-positive bacterium were considered for inclusion in the
study. Patients with blood cultures taken more than five days
before the day of experiment, and patients whose blood cultures
grew Coagulase-negative staphylococci, diptheriod rods, or two or
more bacterial species, were not considered for inclusion. The
medical records for the remaining patients were reviewed, and
patients with hematological malignancies and patients receiving
cytostatic drugs were also not considered. Remaining patients
were offered inclusion.
On the day of experiment, in conjunction with the collection of
blood samples (see below under Blood samples), the patient’s pulse,
blood pressure, breathing frequency, oxygen saturation, and
temperature were recorded. The medical records were reviewed
retrospectively, and data on the current infection as well as
underlying and predisposing diseases, and medication, were
collected from medical records.
Fifteen healthy volunteers who had not taken antiplatelet
medication in the previous ten days were recruited to the study
under the same ethical approval as mentioned above.
Bacteria and culture conditions
Bacterial isolates were collected from the accredited diagnostic
laboratory for Clinical Microbiology, Ska ˚ne University Hospital,
Lund, Sweden. Isolates were classified according to the standard
procedures of this laboratory. Staphylococcus aureus (Newmann),
Streptococcus pyogenes (AP1) [35], Streptococcus pneumoniae (TIGR4),
and Enterococcus faecalis (Bef5) [8] were used as reference bacteria.
On the day of experiment, about 10 colonies of the clinical
isolate taken from a blood agar plate were suspended in 10 ml of
Todd Hewitt Broth (Bacto) and cultivated at 37uC with 5% CO2
to OD620 of 0.5, harvested by centrifugation at 2000 g for
10 minutes, washed once in phosphate buffered saline (PBS), and
suspended in the same buffer. Bacterial concentration was
adjusted by spectrophotometry at 620 nm using a standard curve
obtained for a group G streptococcal strain (G148) to correspond
to 2N10
9 bacteria per ml. After suspension, the bacteria were kept
on ice until experiments were carried out.
Blood samples
After preparing bacterial suspensions, blood samples were
collected from the patient from whom the bacterium had been
isolated. Determination of white blood cell count, absolute
neutrophil count, platelet count, hemoglobin, creatinine, bilirubin,
prothrombin time/international normalized ratio (PT/INR), and
activated partial thromboplastin time (APTT) were performed by
the accredited routine laboratory of Clinical Chemistry and
Pharmacology, Ska ˚ne University Hospital, Lund, Sweden.
Blood for analysis in our research laboratory was collected at the
same time in citrated plastic tubes (BD, Plymouth, UK). For
aggregometry, citrated blood was centrifuged at 160 g for
10 minutes to produce an upper platelet rich plasma (PRP),
which was removed. Subsequent centrifugation at 2000 g for
10 minutes produced an upper platelet poor plasma (PPP).
Aggregometry
A dual channel platelet aggregometer (ChronoLog model 490)
was used to assess platelet aggregation by turbidometry. PPP was
used in the reference cell to establish a baseline of 100%
transmission. PRP was used in the test cell and the change in
transmission over time was an indication of the platelet
aggregation. Twenty ml of bacterial suspension (2N10
9 cfu/ml)
was added to 450 mL of PRP in the test well and the platelet
response was monitored for a maximum of 25 minutes. Two mlo f
soluble collagen I (1 mg/ml) (Triolab, Sweden) was added to
450 ml of PRP as a positive control. Results were analyzed using
the Aggrolink, version 5.2.1 software.
Flow cytometry
For analysis of platelet activation by the bacteria, 20 ml of PRP
was incubated for 25 minutes at room temperature with 40 mlo f
HEPES buffer pH 7.4, either in the presence or absence of washed
bacteria (approximately 1.2N10
7 bacteria) or in the presence of
5 mM adenosine diphosphate (ADP) (Sigma-Aldrich, Steinheim,
Germany). After 25 minutes, 5 mL each of three fluorochrome-
conjugated antibodies (CD42a-PerCP, CD62P-PE, and PAC-
1FITC) (all from BD Biosciences, San Jose, CA US) was added
and after 10 minutes the incubation was stopped by addition of
600 mL of 0.5% formaldehyde in ice cold PBS. Samples were
analyzed using a FACSCalibur flow cytometer in logarithmic
mode with a gate setting for the CD42a positive platelet
population. 30,000 cells were acquired and analyzed using Cell
Quest Software (Becton Dickinson).
For analysis of neutrophil activation and PNC formation in
response to the bacterium that grew in the patient’s blood, 20 mlo f
citrated whole blood from the patient was incubated for
10 minutes at room temperature with 40 ml of the same buffer
as above, either in the presence or absence of bacteria
(approximately 1.2N10
7 washed bacteria) or in the presence of
5 mM ADP and 1 mM fMLP (Sigma-Aldrich). After 10 minutes,
5 mL each of three fluorochrome conjugated antibodies (CD45-
FITC from DAKO, and CD61-PE and CD11b-PeCy5 from BD
Biosciences) was added and after 10 minutes the incubation was
stopped, and erythrocytes were lysed, using the Uti-lyse kit
(DAKO, Glostrup, Denmark). Samples were analyzed as above
but in linear mode with a gate setting for the part of the population
that had a forward and side scatter characteristic of neutrophils
and was CD45-FITC positive. 10,000 cells were acquired and
analyzed using Cell Quest software (Becton Dickinson). CD61-
positive neutrophils were considered to be PNCs. The percentage
of the total neutrophil population positive for CD61 (that is,
associated with platelets) is given as the % PNCs. Neutrophil
activation was expressed as the Mean Fluorescence Intensity (MFI)
of CD11b-PeCy5 of the neutrophil population.
Statistical analysis
Data are expressed, if nothing else is stated, as medians 6 the
interquartile range.
Relative platelet activation, neutrophil activation, and PNC
formation by bacteria was calculated as the value of the respective
marker (CD62P on platelets, MFI of CD11b on neutrophils, and
CD61 on neutrophils) induced by bacteria minus the value in the
unstimulated sample from the same donor. This value was divided
by the value of the same marker induced by ADP and ADP/
fMLP, respectively, minus the value in the unstimulated sample.
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version 5.03 for Windows (GraphPad Software, San Diego, CA,
US). Fisher’s exact test was performed using an interactive
calculation tool available from http://www.quantpsy.org. P-
values,0.05 were considered statistically significant.
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